Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Swedish Orphan Biovitrum publ AB and Biogen Idec Inc announce results of phase 3 study with ALPROLIX


Thursday, 5 Dec 2013 02:00am EST 

Swedish Orphan Biovitrum publ AB and Biogen Idec Inc:Say they announced the publication of detailed results from the pivotal Phase 3 study of ALPROLIX, the companies' investigational long-lasting recombinant factor IX Fc fusion protein candidate for haemophilia B.Say the study appears in the Online First edition and will appear in the Dec. 12 print issue of The New England Journal of Medicine.Say the study of ALPROLIX showed that people with severe haemophilia B safely and effectively prevented or reduced bleeding episodes with prophylactic infusions every one to two weeks. 

Company Quote

66.6
0.15 +0.23%
17 Apr 2014